According to the BVA, the problem is usually related to the cost of treatment, with 90% of vets saying that they or a member of their team have been challenged over their fees or charges and 98% saying that at some time they feel under pressure to waive fees or accept the promise of late payment.
Predictably, the problem is more commonly reported by those working in companion animal or mixed practice, with 89% reporting some form of intimidating experience. Younger vets and female vets were also significantly more likely to have experienced some form of intimidation.
The survey has prompted the BVA and the British Veterinary Nursing Association to issue advice concerning how to deal with intimidating clients.
BVNA President Sam Morgan said: "These statistics make for sad reading, but are certainly not surprising. Working within practice we have all either been subject to or witnessed that 'difficult' client, but we must remember any form of harassment is unacceptable. It’s important not to feel alone in these situations and to ensure there is awareness and support throughout the veterinary team."
BVA President John Fishwick, said: "Every situation is different and has to be dealt with on an individual basis, but it’s concerning to see the figures around challenging client behaviour and fees. Owning an animal is an important responsibility and will cost tens of thousands of pounds over its lifetime.
"It’s important for everyone in the vet team to take pride in the healthcare and treatment they deliver, and, equally, they must feel valued for their services. These figures emphasise the importance of managing expectations around fees by ensuring a two-way discussion about options and costs so clients can make a decision in collaboration with the veterinary team."
The BVA/BVNA advice for dealing with intimidating clients is as follows:
Photo: Dimitry A / Shutterstock
The Royal College of Veterinary Surgeons has launched an online quiz to test its members' knowledge of the Guide to Professional Conduct.
The Guide outlines what is acceptable professional and ethical behaviour for veterinary surgeons. It is developed and maintained by the Advisory Committee of the RCVS, which, in addition to veterinary members of RCVS Council, also includes lay members, a member of the Veterinary Nurses Council, and independent (ie non-Council) veterinary surgeons. The Guide is the benchmark against which a veterinary surgeon is judged, by both the Preliminary Investigation and Disciplinary Committees.
The quiz, which was road-tested at the London Vet Show on 6-7 November, is anonymous, but the College will be collating data on results to help focus future communications activities and see where extra guidance may be required.
On completion of the quiz, it is possible to review answers and view the relevant section of the online Guide.
The quiz is aimed at veterinary surgeons: if it's a success, a version for Registered Veterinary Nurses will follow.
To try the quiz, visit www.rcvs.org.uk/guidequiz It will initially be online for three months and reviewed thereafter.
Rodney (pictured right) has spent the last 26 years practising in the USA, latterly at the California-based Advanced Veterinary Specialists & Animal Specialty Group.
After growing up in Zimbabwe and graduating from the University of Pretoria in South Africa in 1985, he moved to London, where he became an MRCVS, and thence to the USA.
He undertook a small animal internship at the Animal Medical Centre in Manhattan, before moving to the Ohio State University for his residency in medical oncology in 1989. He achieved Board Certification in medical oncology in 1994 and in radiation oncology in 2000.
Rodney specialises in the application of multi-modality therapy protocols for the treatment of cancer in animals, and has conducted research on the phenomenon of multi-drug resistance, mast cell tumour and oral melanoma.
He said: "Thirty-something years on, I have come back to the UK as a specialist, where I started as a GP. Living in the UK also brings me much closer to my family, which is very important to me.
"Over the years, veterinary practice in the USA has changed significantly, where it has become more corporate and less personal. I enjoy being part of a new group where typically it is much closer, friendlier and more like a family."
Rodney now plans to oversee the development of a comprehensive oncology department to include chemotherapy, surgery, radiation therapy, immune-therapy and molecular targeted therapy.
He said his work at Paragon will focus on educating referring vets and clients about what is possible in the oncology field.
He said: "My job will be about increasing the level of knowledge, both of owners and general practitioners, of how we treat cancer in animals.
"It can be a scary disease and the first door an owner needs to step through, is understanding that treating a pet is very different to treating a human.
"The intention in humans is usually to cure but with pets, it is more about providing a good quality of life for as long as possible.
"There can be a fear of cancer therapy but if you stick to the protocols, it is no different to treating any other chronic incurable diseases. We use the safest methods with an abundance of caution and try to make sure that the treatment is not worse than the disease.
"It’s about internal training too, from reception right up to nurses and interns, looking at what we do and how we do it, to optimize the quality of life of the pet and their owners.
"I would like to see an oncology department that considers the emotional, financial, time and patient concerns of the owners, so they feel their commitment to cancer treatment for their pet is not a commitment to putting their pet or themselves through a difficult time."
The product is marketed in a 10ml pack and has an expiry date of December 2017. The batch number is 6231-90D.
The 1ml syringe within the pack has 'Lbs' printed as the unit of measure instead of kg, which could lead to an incorrect dose being administered to dogs.
Any queries about returning this product should be addressed to:
Mr Ken Allen Qualified Person and Quality Advisor E-mail: ken.allen@norbrook.co.ukTelephone: + 02830 264435
‘Is neutering dogs doing more harm than good?’ (BVA Congress Theatre, Thursday 16th November 2023 at 10.30am), will explore the latest research into the science of neutering and its impact on dog health and welfare, particularly on behaviour, and will also consider the role of non-surgical alternatives.
The session will be chaired by BVA President Dr Anna Judson, joined by:
The BVA says statistics from its Voice of the Veterinary Profession survey show that among clients who chose to neuter their dogs last year, only 6% picked non-surgical options.
Awareness of these options is low, with vets reporting that 9% of their clients had requested information about non-surgical options when considering neutering, such as sustained-release implants to suppress testosterone production in male dogs.
Among those who considered non-surgical options, clients cited the cost and need for repeat treatments as their main concerns (mentioned by 67% and 58% of vets, respectively), followed by individual variation in the effect and duration of non-surgical alternatives (22% of vets).
Anna said: “Canine neutering is a firmly established part of preventive pet healthcare in the UK, but it is also very much a live discussion within the veterinary profession, with a healthy ongoing debate around its merits and risks, based on evolving evidence.
"BVA’s survey shows low awareness among clients about all available neutering options for their pets, with only a tiny percentage choosing to go down the non-surgical route.
“Our BVA Congress discussion will offer vet professionals in small animal practice insight into the latest research on neutering, including potential longer-term impacts on a dog’s health and behaviour, and views on what that might mean for how vets discuss neutering options with clients.
"The panellists will also share useful tips on how to deal with clients’ questions about surgical and non-surgical options for their pets.”
https://bvajournals.onlinelibrary.wiley.com/toc/20427670/2023/193/S1
Robexera is a COX2 NSAID formulation which delivers anti-inflammatory pain relief with a once-a-day dosing regime2,3,4.
The product is presented as a flavoured chewable tablet for easier administration by pet owners.
For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.
Charlotte Read, Krka’s UK Key Account Manager, said: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs5.
"This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera.
“Bioequivalent to the originator product6, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”
Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”
Robexera is now available to order from all national UK veterinary wholesalers.
References
Mr Rushton was convicted of sexual assault after pleading guilty at Wood Green Crown Court in December 2022.
He was sentenced to 18 months’ imprisonment, made subject to a restraining order and a 10-year sexual harm prevention order as well as being placed on the Sex Offenders Register for 10 years.
He was also ordered to pay £3,000 costs and a £140 victims’ surcharge.
Mr Rushton did not attend the RCVS hearing, where the facts of the charge were proven by the certificate of conviction and the judge’s sentencing remarks.
In considering whether the conviction rendered Mr Rushton unfit to practise veterinary medicine, the Committee considered that the case involved the sexual assault of a vulnerable woman who was also a professional colleague, and was a serious abuse of trust, reflected in the custodial sentence.
Dr Neil Slater MRCVS, chairing the Committee and speaking on its behalf, said: “It was evident from the judge’s sentencing remarks that [the victim] had been seriously affected by the knowledge of what had occurred on that evening.
"That knowledge was bound, in itself, to be very distressing and according to the victim’s impact statement had a long- lasting impact on the victim’s self-esteem, resilience and relationship with others.
"The victim’s level of distress can only have been increased by the knowledge that the respondent had filmed and/or photographed his activity while she was unconscious and that the images were included on a memory stick which contained a number of other voyeuristic images.”
"The Committee was satisfied that the respondent’s behaviour had caused [the victim] significant psychological injury and carried with it a risk of causing such injury.
“The Committee was also satisfied that [the victim] was especially vulnerable because of the significant quantity of alcohol that she had consumed.
"In the circumstances that evolved, she was in the respondent’s care.
"The respondent abused the position of trust and responsibility that he occupied.
"He was a senior colleague, at a professional conference.
"Instead of taking appropriate steps to secure the welfare of [the victim], he used the position in which he found himself to engage in predatory sexual misconduct.
"Furthermore, his behaviour was opportunistic and, as the judge said, “clearly driven by [his] sexual desires."
Taking into account these factors, the Committee found that Dr Rushton was unfit to practise and next considered the sanction.
The Committee found no mitigating factors regarding the conviction but did take into account the fact there had been no previous regulatory findings against him.
In deciding the sanction, the Committee also noted that there was little evidence before them that Dr Rushton had shown serious insight into the impact of his offending.
Neil added: “In this context the Committee also noted that the respondent maintained a plea of not guilty until three days before a rearranged trial was due to take place, and subsequently advanced an account of what he said was his relationship with [the victim] which the judge found to be false.
“Taking all of these factors into account, the Committee is satisfied that removal from the register is the only proportionate outcome to this case.
"This sanction is necessary to declare and uphold appropriate standards of conduct for members of the veterinary profession and to maintain public confidence in the profession.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Your tip could be clinical in nature (perhaps specific to a particular discipline, like cardiology or exotics), or to do with practice management, or dealing with clients, or HR, or, well, anything really.
To enter the competition, login to VetSurgeon.org and submit your tip in the forum, here.
Just before you press the button to post your tip, you might like to tick the box marked: "EMAIL ME REPLIES TO THIS POST" which appears immediately above the post button. That way, you'll get an email when someone else posts a tip.
Above each post in the forum, there is now a 'Thank You' link, which allows members to express their thanks for sharing something. The five tips that generate the largest number of 'thank yous' by the end of November will win the Amazon vouchers.
VetSurgeon.org is all about facilitating the sharing of knowledge, ideas and experience. So any tip entered into the competition will also be disseminated, together with the contributor's name, on other social media channels, such as Facebook, Twitter, Linkedin and if you include a photo, on Instagram.
VetSurgeon.org Arlo Guthrie said: "The competition is really designed to show off the new 'thank you' feature on VetSurgeon, which allows members to show their appreciation when someone shares something useful with their peers. In due course, we'll be running similar competitions for the most thanked photos and videos uploaded to our galleries. Watch this space."
BVA’s Voice of the Veterinary Profession survey panel, which polls over 1,000 UK vets, highlighted that many vets support the higher welfare standards of British farming, with 9 out of 10 vets saying they would be more likely to buy food if it was labelled as British or locally sourced. Over three quarters of vets said that they would be more likely to buy free-range (77%) or food that carried a Farm Assurance Scheme label (over 50% for Red Tractor and RSPCA Assured; formerly known as Freedom Food).
BVA President Sean Wensley encouraged consumers to check labels as the warmer weather sees BBQs and picnics take centre stage in gatherings of families and friends. He said: "Animal welfare should be a paramount consideration whether we’re thinking about purchasing pets or the food we eat. For vets it’s a top priority that the animals we rear for food have a good life and a humane death.
"Vets are not alone in caring about where their food comes from. To support high standards of animal welfare, all of us can vote for good animal health and welfare through our thoughtful meat, fish, and dairy purchases and send a strong message to food producers and retailers this summer."
BVA’s Voice of the Veterinary Profession survey panel also revealed that 9 out of 10 vets would be less likely to buy meat or fish if it was labelled as not stunned prior to slaughter.
BVA is leading a campaign to end slaughter without pre-stunning for animal welfare reasons and calling for better labelling of food to help consumers make pro-animal welfare choices.
To find out more about BVA’s campaign to end non-stun slaughter, visit: http://www.bva.co.uk/News-campaigns-and-policy/Campaigns/An-end-to-non-stun-slaughter
Image: CC BY-SA 2.0 cyclonebill
MSD Animal Health has announced a new claim for Bovilis BVD and Bovilis IBR Marker Live vaccines which means they can be mixed and administered in a single syringe.
MSD says the new mixing claim will offer significant advantages in herd health planning when controlling two of the more important infectious diseases in cattle.
Bovine Viral Diarrhoea (BVD) and Infectious Bovine Rhinotracheitis (IBR) remain major threats to cattle health and productivity. Vaccinations are commonly given at housing and/or turnout, which are both busy times for veterinary surgeons and on the farm in the herd health planning calendar.
The mixed vaccines are suitable only for booster vaccinations of animals from 15 months of age previously vaccinated separately with Bovilis IBR Marker Live and Bovilis BVD. The mixed vaccine needs to be used within three hours.
MSD says the mixing procedure is clear and easy, but there is an instructional video here: http://www.msd-animal-health.co.uk/Mixing_bovilis_BVD_Bovilis_IBR-Marker_Live.aspx
The Care About Cushing’s website is designed to give horse owners the information they need to spot the signs of Cushing's, thereby prompting diagnosis by their veterinary surgeon.
The online resource includes monitoring tools, personalised alerts, owner guides and webinars. It also offers downloadable self-assessment checklists on Cushing’s disease and laminitis to take owners through the signs to look out for.
Owners whose horses have been diagnosed with Cushing’s are encouraged to sign up as a Care About Cushing’s member to keep up-to-date with the latest information about the disease and create a personal profile for their horse in order to monitor progress. One of the membership benefits is an 'ask the expert' section where members can ask questions about Cushing’s disease and laminitis.
The Care About Cushing’s resource supports Boehringer’s ‘Talk About Laminitis’ initiative to raise awareness of the signs of laminitis and its link with Cushing’s disease.
Talk About Laminitis now runs throughout the year and as part of the campaign the laboratory fees for the blood test which detects Cushing’s (the basal ACTH test) are free.
Liz Barrett, equine business head at Boehringer, said: "Our Talk About Laminitis disease awareness initiative has been hugely successful in highlighting the link between laminitis and Cushing’s disease and helping to diagnose Cushing’s. So much so that Cushing’s is now in the top five equine diseases recorded in the UK1."
For further information on Talk About Laminitis or Care About Cushing’s, visit www.talkaboutlaminitis.co.uk, www.careaboutcushings.co.uk or contact your local Boehringer territory manager.
Reference
Merial Animal Health has announced that it has purchased the the anti-inflammatory treatment for lameness in horses, Hyonate® (sodium hyaluronate), from Bayer.
Merial's equine marketing and technical manager, Louise Radford MRCVS said: "Hyonate is an established treatment of lameness in horses due to non-infectious inflammation of joints, using both intra-articular (IA) and intravenous (IV) injection.
"The beneficial effects of HA supplementation are attributable to the anti-inflammatory effects, improvement in viscoelastic properties of the synovial fluid, and interaction with the synovial membrane affecting pain transmission and joint metabolism¹."
For more information telephone Customer Support on 0870 6000123 or contact your local Merial Equine Specialist.
Zenifel contains synthetic feline facial pheromones which imitate the facial F3 pheromone which has been found to be significantly important when it comes to cats creating areas they feel safe and relaxed in1.
According to the company, Zenifel contains a 48ml vial of the same synthetic F3 feline facial pheromone as the market leader, but, thanks to its own diffusion system and a higher concentration of F3, lasts up to 6 weeks; i.e. 50% longer. This, says Virbac, means that Zenifel is both more economical and more environmentally friendly.
Alongside the launch of the new product, Virbac is offering a practice support pack which includes things you need to create a calm area for feline visitors and promote the benefits of pheromones to pet owners. The company is also running a promotion in which practices could be eligible for a year’s free supply of Zenifel.
For more information, contact your local Virbac Territory Manager.
The dog, called Pepe, needed urgent treatment to repair the cornea before it ruptured, so the team at Davies decided to use a new xenograft derived from a pig cornea, rather than waiting to see if an allograft became available.
The xenograft, which was developed in China, is aseptically prepared, sterilised and freeze-dried so it can be stored for months or years if necessary before use.
According to Davies, the graft had been used in China and the USA, where the early results had been promising. Now, following Pepe's successful treatment, Davies is now using the procedure in more cases over here in the UK.
The full case study, with photos, is here: https://www.vetsurgeon.org/veterinary-clinical/small-animal/sa-ophthalmology/m/photo-video-media/138076.aspx
For more information, visit: https://vetspecialists.co.uk/services/ophthalmology/
For the study, which was funded by the charity Songbird Survival, researchers collected the nests of 103 blue and great tits, and tested them for the presence of 20 insecticides.
Fipronil, imidacloprid and permethrin were the main culprits, detected in 100%, 89.1% and 89.1% of the samples respectively.
Overall, a higher number of either dead offspring or unhatched eggs was found in nests containing a higher number of insecticides, higher total concentration of insecticides or a higher concentration of fipronil, imidacloprid or permethrin, which the authors say suggests contact exposure of eggs to insecticides in nest lining may lead to mortality and lower reproductive success.
The BVA responded by calling for more research and encouraging vets to work with clients to ensure responsible use of parasiticides.
BVA President Elizabeth Mullineaux said: “Parasiticides play an important role in preventing and treating parasites in animals, which if left unaddressed can lead to bigger health and welfare issues in both animals and people.
"But it’s important they are used responsibly, and this work from the University of Sussex and SongBird Survival highlights the need for more research into how parasiticides affect the environment and wildlife and the associated risks.
“Rather than blanket use, we strongly encourage vets and owners to take a risk-based approach to prescribing or recommending these medicines, reflecting an animal’s exposure to parasites."
For the research, the medical histories of 188 Basset Hounds and 270 Dachshunds presenting to CVS’ Dovecote Veterinary Hospital and Chestergates Veterinary Specialists, and the University of Ghent were retrospectively assessed.
Information included signalment, whether the dog had received a diagnosis of TL-IVDE, the duration of clinical signs, affected discs and anatomical region and the neurological grading at presentation and discharge.
Basset Hounds and Dachshunds are both chondrodystrophic breeds which are predisposed to IVDE.
However, the study found 77.4% of Dachshunds had presented with IVDE, compared to only 36.2% of Basset Hounds.
Dachshunds also presented earlier (66.5 months) compared to Basset Hounds (median 87.5 months).
Dachshunds had a lower proportion of midlumbar IVDE and were more frequently non-ambulatory at discharge than Basset Hounds.
In addition, Dachshunds were more likely to be paraplegic without sensation at presentation than Basset Hounds (16/154 Dachshunds compared to just one Basset).
The Basset Hound is the largest chondrodystrophic breed and the physical characteristics of this larger body conformation may have benefits, with previous studies suggesting the protective effects of being a larger dog2.
One hypothesis is whether breed conformation and anatomy – the relative height/weight ratio - influences the severity and occurrence of IVD and points to a link between the size of the patient and the space in the vertebral canal.
A smaller spinal cord versus vertebral canal ratio in the Basset Hound may indicate a less compressive lesion.
Sergio Gomes, Head of Neurology and specialist in veterinary neurology at Dovecote Veterinary Hospital, who led the study, said: “This is the first time that IVDE data for Basset Hounds has been directly compared with that for Dachshunds.
“We now need to look closely at the conformation and anatomy of the Basset Hound to see what learnings we can take.
"This could have positive future implications for Dachshund breeding programmes, so that longer term we can try to minimise this painful and common canine condition.”
The clinic is led by Sebastien Behr MRCVS, an RCVS Specialist in Neurology. Patients will benefit from access to the referral centre's MRI scanner and its specialist imaging, anaesthesia and neurology teams.
Dr Behr said: "We are very excited to have launched this specialist clinic. Following detailed consultations with pet owners, the animals will be treated to the very highest level and bespoke care designed for each patient."
The practice is offering a fixed price package for routine diagnostic procedures.
For more information, visit www.willows.uk.net or contact the neurology team on 0121 721 7070.
Sarah, who practices at Southfields Veterinary Specialists, was already a European and Royal College Specialist in oncology. Now, after studying for a year and passing the European College of Veterinary Internal Medicine (ECVIM) exams this autumn, she has now been recognised as a European Specialist in radiation oncology as well.
Sarah said: "I intend to use my experience to grow the radiation and oncology service at Southfields and, with the benefit of our new linear accelerator and state-of-the-art hospital, deliver the most advanced treatment options for our veterinary patients.
"I also intend to use my experience and expertise to contribute to the further development of radiation oncology as a specialist qualification in Europe."
Congratulations Sarah!
The company says that the composition and dosage of the new product has been optimised for maximum efficacy 1, 2. It offers three-five days on-label treatment options and does not need to be stored in a fridge.
According to Boehringer, the 600mg dose results in a concentration well above MICs for Strep. uberis and Staph. aureus for 24 hours, even after milking, which means it needs to be administered once a day1. In addition, its formulation enables optimum distribution of penicillin throughout the udder2.
Kath Aplin veterinary adviser at Boehringer Ingelheim said: "Traditionally, in the UK, we have favoured broad spectrum mastitis therapy as our first line approach, however in many other European countries, including The Netherlands, Belgium, Sweden and Denmark, penicillin is the treatment of choice.
"For farms with a mixed or unknown mastitis pattern, the traditional broad spectrum approach to mastitis therapy makes sense. However, many vets now have a good knowledge of common mastitis pathogens on clients’ farms and, for those where gram +ve pathogens predominate, penicillin as a first line treatment is well worth considering."
In a field trial assessing the prevalence of mastitis-causing pathogens and clinical cure rates after treatment with Ubropen3, mild and moderate cases of mastitis were treated for three to five days, with the causal pathogen being unknown at the time of treatment.
Kath said: “In 80% of cases of grade one or two clinical mastitis, the causative pathogen was found to be gram +ve and, following treatment with Ubropen, the overall clinical cure rate was 81%".
Ubropen is now available from the usual veterinary wholesalers in boxes of 20 tubes.
References:
Almost half of the vets that watched a webinar about ferret medicine have said they would change their treatment protocols for adrenal disease and reproduction management as a result of what they learned.
The Virbac-sponsored webinar was led by John Chitty BVetMed CertZooMed CBiol MSB MRCVS and viewed by more than 600 practices, making it the most popular CPD event hosted by The Webinar Vet this year.
John Chitty said: "I provided an overview of treatment protocols for all of the common diseases but focused on adrenal disease as it's highly prevalent in neutered ferrets but may be reduced by the routine use of deslorelin implants. These implants can also be used to avoid surgical neutering."
According to a post-webinar questionnaire, 33% of clinicians said that they saw ferrets more than five times a year. Chris Geddes MRCVS, Product Manager at Virbac said: "This confirms what we thought: ferrets are being presented more and more in practice and so education on this species is vital. An amazing 41% of respondents said that they would change their protocols for reproduction management and 40% their treatment of adrenal disease following the webinar, showing how useful it was to those attending."
Virbac recently announced that it has gained a marketing authorisation for the use of Suprelorin 9.4mg in male ferrets. Suprelorin, a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin, offers temporary sterilisation without the need for surgery.
For those who were unable to see it at the time, the webinar can now be viewed by visiting www.virbac.co.uk. A CPD certificate is also available for download as are six other webinars previously sponsored by Virbac.
The Wellington-based hospital is hoping to announce its first resident at the start of next year, who will work under the guidance of Fran Taylor-Brown and Tom Cardy.
This is the first residency programme to be conducted at Cave and has been launched by Fran who, along with Tom, is an EBVS and RCVS specialist in veterinary neurology.
Fran said: "The ECVN accreditation is an important milestone for us as we look to develop and expand our expertise in neurology.
"We are currently undertaking a major recruitment drive and having the capability to offer specialist training in this discipline is another feather in the cap.
"We’re hopeful this approval will open the door to allow clinicians in other disciplines to receive specialist-level training with us in the future."
Cave has also introduced an internship programme to support the growth of the team and has taken on Samantha Gilbert a graduate of James Cook University in Australia.
The company says the system uses a combination of image recognition technology, algorithms and cloud-based artificial intelligence to deliver accurate testing results at the time of visit, within 9 minutes in fact, giving veterinary surgeons the ability to diagnose and treat patients quickly, without the need for a second appointment.
Vetscan Imagyst will detect the eggs, cysts, and oocysts of whipworm, hookworm, roundworm, Giardia, and coccidia
Richard Goldstein, DVM, DACVIM, DECVIM-CA, VP Global Diagnostics Medical Affairs at Zoetis, said: "Parasites are a threat throughout the year, making routine monitoring critical to pet health.
“With Vetscan Imagyst, the ability to have accurate, fast results at the point-of-care empowers veterinarians to diagnose and treat in the same visit, increasing compliance and eliminating follow-up appointments and call backs, thus enhancing the overall pet owner experience.”
Vetscan Imagyst will launch in the UK next week. For more information, contact your Zoetis representative or visit at www.vetscanimagyst.com.
The Government says that contracts have been secured with Brittany Ferries and DFDS to run ferries into and out of Poole, Portsmouth, Plymouth, Immingham and Felixstowe, thereby relieving pressure on the Dover straights.
Critical goods have been identified as those essential for the preservation of human and animal welfare, including all veterinary medicines authorised under the Veterinary Medicines Regulation 2013, including finished and un-finished products, and Active Pharmaceutical Ingredients (for import and export).
Critical goods also include unauthorised medicines permitted for import under the Veterinary Medicines Directorate’s Special Import Scheme (for import only).
Photo: Shutterstock/Peter Hermes Furian
Dechra Veterinary Products has launched a 5 ml bottle of Comfortan (methadone), its titratable analgesia for cats and dogs.
The new sized bottle of Comfortan, designed for use with animals in, or about to experience, moderate to severe pain, is now available from veterinary wholesalers.
Dechra Brand Manager Craig Sankey said: “The new 5ml bottle is a great size for practices which would like to introduce Comfortan into their practice protocols, allowing them to do so in a cost-effective way.
“The availability of a smaller bottle will also be a benefit to practices which due to different surgical needs, currently only use Comfortan in a small number of cases. They will then be able to simply and easily trade up to the 10 ml bottle once they start to use Comfortan on more cases.”
The 5 ml has also been introduced in response to demand from branch practices which had been transferring 10ml bottles between sites and for cat-focused practices which use smaller volumes of the product.
Novartis Animal Health has issued the following statement concerning the supply of acepromazine (ACP) injectable in the UK:
"Recent upgrades to Novartis Animal Health’s manufacturing plant in the UK have resulted in the site becoming a worldwide centre of excellence for the production of bulk liquids. This upgrade has had an impact on the manufacture of ACP 2mg/ml and 10mg/ml injectable products, which will no longer be produced in the UK.
From January 2011, Novartis Animal Health will no longer be able to supply ACP Injection 2mg/ml or ACP Injection 10mg/ml to wholesalers. However, it is not Novartis’ intention to discontinue the supply of acepromazine injectable; in order to ensure consistency of supply to the UK market the company will be importing the Vetoquinol French product Calmivet.
Calmivet is a monovalent acepromazine injection licensed for use in dogs, cats and horses, available as a 5mg/ml injection, 50ml vial.
In order to obtain Calmivet from wholesalers, veterinarians will need to apply for a free of charge Special Import Certificate from the VMD. This can be completed on line at www.vmd.gov.uk.
It is anticipated that this situation will continue for at least the first 6 months of 2011, until an alternative manufacturing site is established. As soon as we have more information on the timelines this will be communicated.
A full communication including a prep room reminder poster and Calmivet product leaflet has been mailed to all UK practices.
Vetoquinol UK are not responsible for the distribution or technical support of this product, so any queries should be directed to Novartis Animal Health UK on 01276 694402.
The production and supply of ACP Tablets 10mg remains unaffected."